About FSHD Canada Foundation
Funded Research

Stryka-001 treatment in the FSHD-like mouse model

Investigator: Dean Burkin, PhD, and Peter Jones, PhD (University of Nevada, Reno School of Medicine) This is a project to validate the efficacy of a potential drug therapy for FSHD…

Read More

A Xenograft Model of FSHD for Testing Therapeutics

Investigator: Robert J Bloch PhD, Professor of Physiology
 at the University of Maryland Facioscapulohumeral muscular dystrophy (FSHD) affects 1 in approximately 15,000 individuals worldwide. One of the obstacles in developing treatments…

Read More

Developing LNA-based therapy for FSHD

Investigators: • Yi-Wen Chen Children’s National Health System (Washington DC) • Toshifumi Yokota University of Alberta Faculty of Medicine and Dentistry (Alberta, Canada) Yi-Wen Chen and Toshifumi Yokota are investigating one…

Read More

Facio Therapies

Facio Therapies (Facio-therapies.com) is a company based in the Netherlands that is focused on finding a cure for FSHD. Facio have screened over 34,000 small molecule compounds, and obtained over…

Read More

FSHD myofibers cultured from human xenografts

FSH Muscular Dystrophy (FSHD) affects 1 in approximately 8,300 individuals worldwide. One of the obstacles in developing treatments for FSHD is the lack of a small animal model of the…

Read More

Determining the effectiveness of increased SMCHD1 expression to suppress DUX4 in FSHD muscle cells and model mice

There are two genetic types of FSHD: FSHD1 and FSHD2. FSHD1 (representing around 95% of FSHD cases) is associated with a loss of repetitive DNA units called D4Z4 on the end of…

Read More
https://twitter.com/#!/FSHDCanada/ http://www.facebook.com/pages/FSHD-Canada/331378503625267 /contact Suite 201, 1100 1st St. SE Calgary, Alberta T2G 1B1 403.470.0141 neil.camarta@fshd.ca